AC Immune SA today announced that based on the Phase 1b/2a interim data, ACI-35.030, a potential first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate, has been selected for further development. The selection of ACI-35.030 is supported by new clinical data from the Phase 1b/2a trial presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2022.
Bharat Biotech Tweeted on November 28, 2022, that iNCOVACC became the world's first intranasal COVID-19 vaccine to receive both primary series and Heterologous booster approval in India. Previously, ANI Tweeted on November 25, 2022, the Drugs Controller General of India had approved Bharat Biotech's Intranasal 'Five Arms' booster dose of iNCOVACC.
Early in 2022, scientists from the Institute for Molecular Medicine (IMM), their collaborators from the University of California, Irvine (UCI), and the National Institute on Aging (NIA) reported on the efficacy of four DNA vaccines based on the universal MultiTEP platform and targeting various regions of pathological α-Synuclein in a mouse model of Dementia Lewy Body (DLB) and Parkinson disease (PD).